Dry Age Related Macular Degenetation (AMD) drug shows positive result in phase 2 trial

NT-501, the lead product candidate of Neurotech Pharmaceutisals, inc., have successfully slowed down the loss of vision in a Phase 2 clinical trial, in patients suffering from macular degeneration along with geographic atrophy(GA). GA is a condition that destroys sharp central vision and causes serious vision loss to one or both eyes.

Full article »


Protected by Comment Guard Pro